Overview

Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness

Status:
Not yet recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective in treating mild or moderate COVID-19 illness in adults and adolescents at highest risk for severe outcomes. Each participant will be followed for approximately 28 days.

Phase:

Phase 3

Details

Lead Sponsor:

Romark Laboratories L.C.

Treatments:

Nitazoxanide